Healthy volunteers test new heart Drug's body processing
NCT ID NCT07133191
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This completed Phase 1 trial studied how a single 16 mg dose of selatogrel is absorbed and processed in the body of 32 healthy volunteers (16 Japanese and 16 Caucasian). The study did not aim to treat any condition, but to gather safety and drug-level data. Participants stayed in the clinic for 3-4 days and had follow-up for about 70 days total.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Selatogrel (a reversible P2Y12 receptor antagonist given as a single injection)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CenExel ACT (Anaheim Clinical Trials)
Anaheim, California, 92801, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults